Tianeptine dose: what do studies and labels say?
| Label | Who | Daily dose |
|---|---|---|
| Singapore HSA, Stablon1 | Recommended dosage | One 12.5 mg tablet three times a day (morning, midday and evening), at the beginning of the main meals |
| Singapore HSA, Stablon1 | Over 70, or renal insufficiency | 2 tablets a day |
| Polish SmPC, Atinepte2 | Recommended dosage (12.5 mg tablet) | One tablet three times a day (morning, midday and evening), before the main meals |
| Polish SmPC, Atinepte2 | Frail, lean elderly patients under 55 kg | Two tablets |
| Polish SmPC, Atinepte2 | Severe renal impairment, creatinine clearance below 19 ml/min | Two tablets |
What the labels give
The table is set at the top of the page
The labels differ on age: the Polish SmPC says no age-based dose adjustment is needed apart from frail, lean elderly patients under 55 kg, the Singapore label restricts subjects aged over 70 years to 2 tablets a day, and a 2024 review gives 25 mg/day for the elderly.213 The FDA states that tianeptine is not approved in the US for any medical use, and a DailyMed search found no US label.4
What the trials used
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Costa e Silva and colleagues, 1997, major depression or bipolar disorder (depressed), against placebo5 | 25-50 mg/day, mean 37.5 mg/day | 126 depressed outpatients | 42 days after a 1-week placebo run-in |
| Kauer-Sant'Anna and colleagues, 2019, bipolar depression, adjunctive, against placebo6 | 37.5 mg/day | 161 participants, 69 randomised (36 tianeptine, 33 placebo) | Eight weeks open-label, then a 24-week double-blind phase |
| NCT04249596, started 2020, treatment-resistant depression, open-label, stopped early7 | Tianeptine sodium 12.5 mg three times daily at 9am, 1pm and 5pm | 38 participants (target 75) | 8 weeks |
| NCT05686408 (UPLIFT), started 2023, major depressive disorder, against placebo, completed8 | TNX-601 ER (tianeptine) 39.4 mg extended-release tablet once daily, or a placebo tablet once daily | 132 participants (64 TNX-601 ER, 68 placebo) | 6 weeks |
| NCT06012552 (COVMENT), started 2023, Covid fog symptoms after COVID-19, against placebo, still recruiting9 | Oral tianeptine 3x 12.5 mg per day (under 70) or 2x 12.5 mg per day (over 70), with group psychotherapy and neurological rehabilitation in both arms | 140 participants (estimated) | 16 weeks |
| NCT01309776 (CAMPION), started 2011, reported by Yoo and colleagues, 2015, major depressive disorder, open-label, against escitalopram 5 mg/day in the first week, then 10 mg/day in the second10 | 25 mg/day once daily in week 1, then 37.5 mg/day twice daily in week 2 | 164 participants | 12 weeks |
Searches returned no completed pain or anxiety trial with results, only registry entries without results.
Half-life and older people
A 2024 review reports that a single 12.5 mg oral dose of the sodium salt in 12 healthy volunteers (6 men and 6 women) peaked at 0.94 ± 0.47 h.3 A 1988 pharmacokinetic paper by Royer and colleagues reports a short mean elimination half-life of 2.5 ± 1.1 h.11 The same paper says the half-life is prolonged by 1 hour in renal failure and in the elderly, suggesting a limit of two tablets per day.11 The Polish SmPC gives an elimination half-life of three hours.2
Stopping tianeptine
The Singapore label says abrupt discontinuation is to be avoided, and both it and the Polish SmPC give a gradual dose reduction over 7 to 14 days to reduce the risk of withdrawal reactions.12 A 2026 systematic review of tianeptine misuse by Anand and colleagues found that, among its 52 individual cases, 26/52 (50%) presented with withdrawal.12
Doses above the labelled ones
The FDA says case reports in the medical literature describe US consumers taking daily doses on the order of 1.3 to 250-fold (50 mg to 10,000 mg) the daily dose typically recommended in labeled foreign drug products.4 The FDA warns consumers not to purchase or use any product with tianeptine, and says it continues to receive severe adverse event reports after use of Neptune's Fix products, including seizures, loss of consciousness and death.4 The Polish SmPC says not to give doses larger than recommended.2
Storage and mixing
The Polish SmPC gives a shelf life of two years and says not to store the tablets above 25°C.2 The French ANSM SmPC for Stablon gives a shelf life of 36 mois (months), with no special storage precautions in climatic zones I and II and storage not above 30°C in climatic zones III and IV.13 Searches of labels, regulator pages, DailyMed, PubMed and trial registries found no tianeptine solution, oral liquid or injectable with a mg/mL concentration and no instruction for mixing a powder with water, so there is no concentration to convert to a syringe mark.
Frequently asked questions
Is tianeptine sulfate dosed differently?
Searches of PubMed and trial registries for tianeptine sulfate, which were not done in depth, returned only sodium salt products and found no labelled sulfate product.
- TianeptineHalf-life, trial results and regulatory status.
- SupplementsOther compounds on Milligram.
- Units and dosingHow mg, mcg and syringe units relate.
- Creatine monohydrateA guide to an oral supplement.
- Cholecalciferol dosageA guide to an oral supplement.
- Omega-3 fish oil dosageA guide to an oral supplement.
References
- Singapore HSA. STABLON TABLET 12.5 MG [SIN11182P]. ndf.gov.sg
- Polpharma SmPC (Poland). CHARAKTERYSTYKA PRODUKTU LECZNICZEGO. polpharma.pl
- PMC. Classics in Chemical Neuroscience: Tianeptine. 2024. pmc.ncbi.nlm.nih.gov
- US FDA. FDA warns consumers not to purchase or use any tianeptine product due. fda.gov
- PubMed. Placebo-controlled study of tianeptine in major depressive episodes. 1997. pubmed.ncbi.nlm.nih.gov
- PubMed. Adjunctive tianeptine treatment for bipolar disorder: A 24-week randomized, placebo-controlled, maintenance trial. 2019. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT04249596: Tianeptine for Treatment Resistant Depression. 2026. clinicaltrials.gov
- ClinicalTrials.gov. NCT05686408: Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD). 2025. clinicaltrials.gov
- ClinicalTrials.gov. NCT06012552: Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Tianeptine in the Treatment of Covid Fog Symptoms in Patients After COVID-19. 2027. clinicaltrials.gov
- ClinicalTrials.gov. NCT01309776: Comparison of Tianeptine Versus Escitalopram Patients Major Depressive Disorder. 2012. clinicaltrials.gov
- PubMed. Pharmacokinetic and metabolic parameters of tianeptine in healthy volunteers and in populations with risk factors. 1988. pubmed.ncbi.nlm.nih.gov
- PubMed. Tianeptine misuse and addiction: A systematic review of withdrawal, toxicity, and clinical management. 2026. pubmed.ncbi.nlm.nih.gov
- ANSM France. R�sum� des Caract�ristiques du Produit. agence-prd.ansm.sante.fr